Alicaforsen (ISIS 2302) in Patients With Active Crohn's Disease
ISIS 2302-CS21, Phase 3 Double-Masked, Placebo-Controlled Study of Alicaforsen (ISIS 2302), an Antisense Inhibitor of ICAM-1, for the Treatment of Patients With Active Crohn's Disease
Sponsor: Ionis Pharmaceuticals, Inc.
A PHASE3 clinical study on Crohn's Disease, this trial is completed. The trial is conducted by Ionis Pharmaceuticals, Inc. and has accumulated 8 data snapshots since 2002. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Status Flow
Change History
8 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE3
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE3
-
Sep 2022 — Jul 2024 [monthly]
Completed PHASE3
Status: Unknown Status → Completed
-
Jan 2021 — Sep 2022 [monthly]
Unknown Status PHASE3
▶ Show 3 earlier versions
-
Sep 2020 — Jan 2021 [monthly]
Unknown Status PHASE3
-
Jun 2018 — Sep 2020 [monthly]
Unknown Status PHASE3
-
Jan 2017 — Jun 2018 [monthly]
Unknown Status PHASE3
First recorded
May 2002
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Ionis Pharmaceuticals, Inc.
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Barcelona, Spain , Hradic Kralove 2, Czechia , Kortrijk, Belgium , Krakow, Poland , Minden, Germany , Münster, Germany , Olomouc, Czechia , Prague, Czechia , Roeselare, Belgium , Szczecin, Poland and 5 more locations